用托法西提尼布治疗的性结肠炎患者的组织学结果和JAK-STAT信号
Sara van Gennep1, Ivan C N Fung2, Djuna C de Jong1
1Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands.
Journal of Crohn's & colitis
|March 20, 2024
概括
托法西替尼治疗显著改善了性结肠炎患者的组织学结果,减少了关键的炎症标志物,如STAT1,STAT3和STAT5. 这表明tfacitinib有效地针对UC治疗的JAK-STAT途径.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 雅努斯酶-STAT (JAK-STAT) 信号通路在UC病变发生过程中起着至关重要的作用.
- 托法西提尼布是一种口服的JAK抑制剂,用于UC治疗.
研究的目的:
- 评估UC患者托法西提尼布治疗的组织学结果.
- 评估托法西提尼布对UC中JAK-STAT信号的影响.
- 为了将组织学改善与特定的信号通路变化相关联.
主要方法:
- 在40名UC患者的前性队列研究中,他们每天两次服用托法西提尼布10毫克,持续8周.
- 使用罗巴特斯基因病理学指数 (RHI) 的组织学评估.
- 免疫组织化学 (IHC) 用于测量JAKs (JAK1-3,TYK2) 和STATs (STAT1-6) 的粘膜表达.
主要成果:
- 38%的患者在8周内实现了组织内镜粘膜改善 (HEMI),58%的患者在8周内实现了组织学缓解 (RHI ≤3).
- 在响应者和非响应者中观察到RHI的显著下降.
- 托法西替尼治疗导致STAT1,STAT3和STAT5表达的显著减少.
- 较低的第8周STAT1表达与更好的治疗反应相关.
结论:
- 在大多数UC患者中,托法西替尼治疗显著改善了组织学结果.
- 该药物有效地抑制了JAK-STAT通路的关键组件,包括STAT1,STAT3和STAT5.
- 组织内镜粘膜改善与更深层次的STAT1抑制有关,表明其在治疗疗效方面的作用.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K


